Updated

Researchers used CRISPR gene editing to remove the CD33 marker from donor stem cells, potentially allowing doctors to target aggressive blood cancers with CD33-directed treatments without destroying the healthy blood cells patients need after a transplant. In a 30-patient trial, the edited cells successfully engrafted and appeared to shield normal blood cells from the cancer therapy. The approach could offer a safer way to combine targeted cancer treatment with stem cell transplantation, potentially reducing complications for patients undergoing treatment for aggressive blood cancers.